BRD3308

BRD3308 is a highly selective HDAC3 inhibitor with an IC50 of 54 nM. BRD3308 is 23-fold selectivity for HDAC3 over HDAC1 (IC50 of 1.26 μM) or HDAC2 (IC50 of 1.34 μM) . BRD3308 suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release. BRD3308 activates HIV-1 transcription and disrupts HIV-1 latency[1][2][3].

Product Specifications

CAS Number

1550053-02-5

UNSPSC

12352005

Hazard Statement

H315, H319

Target

Apoptosis; HDAC; HIV

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Applications

COVID-19-anti-virus

Field of Research

Infection; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/brd3308.html

Purity

98.34

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(C)NC1=CC=C(C(NC2=CC=C(F)C=C2N)=O)C=C1

Molecular Formula

C15H14FN3O2

Molecular Weight

287.29

Precautions

H315, H319

References & Citations

[1]Barton KM, et al. Selective HDAC inhibition for the disruption of latent HIV-1 infection. PLoS One. 2014 Aug 19;9 (8) :e102684.|[2]Lundh M, et al. Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats. Diabetes Obes Metab. 2015 Jul;17 (7) :703-7.|[3]Wagner FF, et al. An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection. ACS Chem Biol. 2016 Feb 19;11 (2) :363-74.